October 7, 2015 - ZOLL LifeVest Wearable Defibrillator to Be Showcased at TCT 2015

CONTACT:

Diane Egan
ZOLL Medical Corporation
+1 (978) 421-9637
degan@zoll.com
 

ZOLL LIFEVEST WEARABLE DEFIBRILLATOR TO BE SHOWCASED AT TCT 2015

October 7, 2015—CHELMSFORD, MASS.—ZOLL® Medical Corporation, an Asahi Kasei Group Company that manufactures medical devices and related software solutions, announced today that it will display the LifeVest® Wearable Defibrillator, along with sudden cardiac death (SCD) education and screening tools, in Booth 1405 at the 2015 Transcatheter Cardiovascular Therapeutics (TCT) meeting, October 11–15 in San Francisco.

The LifeVest protects patients at risk for SCD. It is used for a wide range of patient conditions or situations, including following a recent myocardial infarction or coronary revascularization. One in five post–acute myocardial infarction (AMI) patients have been shown to be at high risk of dying after percutaneous coronary intervention (PCI).1 The majority of mortality in AMI patients post–PCI occurs in the first three months—one out of every 10 high-risk patients die, with about 60% of this mortality due to SCD.1,2 The LifeVest gives physicians time to optimize medical therapy and assess a patient’s long-term risk for sudden death.

In the WEARIT-II prospective registry of 2,000 patients prescribed the LifeVest, the sustained VT/VF event rate was high with 22 events per 100 patient-years—2.1% of patients had a VT/VF event.3 One in 14 patients experienced a clinically meaningful arrhythmia requiring intervention while wearing the LifeVest.3 The LifeVest Network online patient data management system provides customizable tools for physicians and clinicians to access these captured arrhythmias, like atrial fibrillation or non-sustained ventricular tachyarrhythmias, and determine the appropriate intervention.

The LifeVest is lightweight and easy to wear, allowing patients to return to their common activities of daily living, while having the peace of mind that they are protected from SCD. The LifeVest continuously monitors the patient’s heart and, if a life-threatening heart rhythm is detected, the device delivers a treatment shock to restore normal heart rhythm.

The LifeVest is covered by most health plans in the United States, including commercial, state, and federal plans.

About ZOLL Medical Corporation

ZOLL Medical Corporation, an Asahi Kasei Group Company, develops and markets medical devices and software solutions that help advance emergency care and save lives, while increasing clinical and operational efficiencies. With products for defibrillation and monitoring, circulation and CPR feedback, data management, fluid resuscitation, therapeutic temperature management, and ventilation, ZOLL provides a comprehensive set of technologies that help clinicians, EMS and fire professionals, and lay rescuers treat victims needing resuscitation and acute critical care. For more information, visit www.zoll.com.

About Asahi Kasei

The Asahi Kasei Group is a diversified group of companies led by holding company Asahi Kasei Corp., with operations in the chemicals and fibers, homes and construction materials, electronics, and health care business sectors. Its health care operations include devices and systems for acute critical care, dialysis, therapeutic apheresis, transfusion, and manufacture of biotherapeutics, as well as pharmaceuticals, diagnostic reagents, and nutritional products. With more than 30,000 employees around the world, the Asahi Kasei Group serves customers in more than 100 countries. For more information, visit www.asahi-kasei.co.jp/asahi/en/.

1Halkin A, et al. Prediction of Mortality After Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction: CADILLAC Risk Score. JACC. 2005;45:1397–1405.
2Stone G, et al. Prevention of Sudden Cardiac Arrest Post PTCA in High-Risk Patients. http://www.theheart.org/article/1202823.do (April 2011).
3Kutyifa V, et al. Results from the Prospective Registry of Patients Using the Wearable Defibrillator (WEARIT-II Registry), presented as Late Breaking Clinical Trial at the European Society of Cardiology Congress, September 3, 2014.
 

Copyright © 2015 ZOLL Medical Corporation. LifeVest and ZOLL are trademarks or registered trademarks of ZOLL Medical Corporation in the United States and other countries. Asahi Kasei is a registered trademark of Asahi Kasei Corporation. All other trademarks are the property of their respective owners.